← Back to Screener
Alpha Cognition Inc. Common Stock (ACOG)
Price$6.89
Favorite Metrics
Price vs S&P 500 (26W)-9.89%
Price vs S&P 500 (4W)12.05%
Market Capitalization$150.02M
All Metrics
Book Value / Share (Quarterly)$2.09
P/TBV (Annual)2.16x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.98
Price vs S&P 500 (YTD)2.63%
EPS (TTM)$-1.37
10-Day Avg Trading Volume0.07M
EPS Excl Extra (TTM)$-1.37
EPS (Annual)$-2.02
ROI (Annual)-34.54%
Cash / Share (Quarterly)$2.18
ROA (Last FY)-28.85%
EBITD / Share (TTM)$-1.16
Cash Flow / Share (Annual)$-0.49
P/B Ratio4.42x
P/B Ratio (Quarterly)4.01x
Net Income / Employee (Annual)$-0
Net Interest Coverage (TTM)-3.54x
ROA (TTM)-40.83%
EPS Incl Extra (Annual)$-2.02
Current Ratio (Annual)15.00x
Quick Ratio (Quarterly)5.61x
3-Month Avg Trading Volume0.07M
52-Week Price Return63.29%
Tangible BV / Share (Quarterly)$2.06
52-Week High$11.54
EPS Excl Extra (Annual)$-2.02
26-Week Price Return-1.14%
Quick Ratio (Annual)14.49x
13-Week Price Return17.03%
Total Debt / Equity (Annual)0.02x
Current Ratio (Quarterly)6.69x
Enterprise Value$114.625
Revenue / Employee (Annual)$0
Cash / Share (Annual)$3.03
3-Month Return Std Dev75.56%
Net Income / Employee (TTM)$-0
ROE (Last FY)-35.30%
EPS Basic Excl Extra (Annual)$-2.02
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.37
ROI (TTM)-52.28%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.56
Price vs S&P 500 (52W)28.20%
Year-to-Date Return6.77%
5-Day Price Return16.25%
EPS Normalized (Annual)$-2.02
Month-to-Date Return26.41%
EBITD / Share (Annual)$-1.56
EPS Basic Excl Extra (TTM)$-1.37
P/TBV (Quarterly)4.06x
P/B Ratio (Annual)2.14x
Book Value / Share (Annual)$2.59
Price vs S&P 500 (13W)14.17%
Beta9.19x
ROE (TTM)-52.60%
52-Week Low$3.97
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ACOGAlpha Cognition Inc. Common Stock | — | — | — | — | $6.89 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Alpha Cognition Inc is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases, including Alzheimer's disease. The company markets ZUNVEYL, an oral tablet formulation, and is building a commercial team targeting the long-term care market with a focus on positioning ZUNVEYL against existing acetylcholinesterase inhibitor treatments. The company is also pursuing licensing partnerships to expand ZUNVEYL's indications and formulations.